Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ518MR)

This product GTTS-WQ518MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ518MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4842MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ4257MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ2514MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ10059MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ15594MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ7829MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ13490MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4698MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.